Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced its unaudited business highlights and financial results for the three-month period ended June 30, 2021. In the report, the company noted it had become the first psychedelic company to list on the NYSE American LLC stock exchange, a milestone reached on Aug. 5, 2021; raised more than C$120 million with the inclusion of its latest equity financing round; achieved certain milestones by wholly owned subsidiary Adelia Therapeutics Inc.; initiated the next phase of its digital therapeutics platform designed to evaluate patient outcomes through a highly secure, patient-centered data analytics platform for pre- and post-psychedelic treatments; started scale up of its European operations and research activities; expanded its patent portfolio to 13 patent filings; and entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers Inc. Financially, the company reported total cash and cash equivalents of C$55.1 million for the quarter ending June 30, 2021, and net loss of C$14.7 million for the same period, of which noncash expenses totaled C$5.6 million and cash-based operating expenses totaled C$9.1 million. “During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space,” said Cybin CEO Doug Drysdale in the press release. “We believe the molecules we have under development may have the potential to transform the treatment landscape and fill current unmet treatment needs for various psychiatric and neurological conditions. We look forward to sharing updates as we advance our pre-clinical and clinical programs and continue the scientific exploration that we believe will ultimately provide safer and more effective treatments for those suffering with mental illness and addiction issues.”
To view the full press release, visit
https://ibn.fm/QCrl4
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at
www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at
https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates
PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit
https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW?
Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the
InvestorBrandNetwork.